Brief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
03/06/2026 11:28
BRIEF-MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf June 3 (Reuters) - MannKind Corp MNKD.O:
MANNKIND ENTERS DATA-RICH DEVELOPMENT PERIOD WITH COMPLETION OF RANDOMIZATION IN PHASE 1B INFLO-1 STUDY AND ENROLLMENT OF FIRST PATIENT IN PHASE 2 INFLO-2 TRIAL FOR NINTEDANIB DPI IN PATIENTS WITH IPF
MANNKIND - EXPECTS PHASE 1B INFLO-1 DATA READOUT IN Q3 2026
Source text: ID:nGNX84ZNyQ
Further company coverage: MNKD.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children